Avior Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.51M | Sell |
3,045
-9
| -0.3% | -$3.99K | 0.04% | 290 |
|
|
2026
Q1 | $1.36M | Sell |
3,054
-248
| -8% | -$116K | 0.04% | 296 |
|
|
2025
Q4 | $1.5M | Buy |
3,302
+164
| +5% | +$70.7K | 0.05% | 240 |
|
|
2025
Q3 | $1.23M | Buy |
3,138
+188
| +6% | +$78.6K | 0.04% | 269 |
|
|
2025
Q2 | $1.31M | Buy |
2,950
+648
| +28% | +$299K | 0.05% | 239 |
|
|
2025
Q1 | $1.12M | Sell |
2,302
-667
| -22% | -$311K | 0.04% | 246 |
|
|
2024
Q4 | $1.2M | Buy |
2,969
+436
| +17% | +$202K | 0.04% | 251 |
|
|
2024
Q3 | $1.18M | Buy |
2,533
+113
| +5% | +$54.3K | 0.05% | 257 |
|
|
2024
Q2 | $1.13M | Sell |
2,420
-686
| -22% | -$298K | 0.05% | 244 |
|
|
2024
Q1 | $1.3M | Buy |
3,106
+384
| +14% | +$162K | 0.06% | 234 |
|
|
2023
Q4 | $1.11M | Buy |
2,722
+48
| +2% | +$17.7K | 0.07% | 193 |
|
|
2023
Q3 | $930K | Hold |
2,674
| – | – | 0.06% | 207 |
|
|
2023
Q2 | $941K | Hold |
2,674
| – | – | 0.06% | 208 |
|
|
2023
Q1 | $842K | Sell |
2,674
-251
| -9% | -$75.3K | 0.06% | 224 |
|
|
2022
Q4 | $845K | Sell |
2,925
-112
| -4% | -$34.1K | 0.06% | 210 |
|
|
2022
Q3 | $878K | Sell |
3,037
-119
| -4% | -$34.2K | 0.07% | 183 |
|
|
2022
Q2 | $889K | Sell |
3,156
-964
| -23% | -$258K | 0.09% | 160 |
|
|
2022
Q1 | $1.07M | Sell |
4,120
-630
| -13% | -$150K | 0.09% | 155 |
|
|
2021
Q4 | $1.04M | Hold |
4,750
| – | – | 0.09% | 191 |
|
|
2021
Q3 | $861K | Buy |
4,750
+2,430
| +105% | +$474K | 0.07% | 209 |
|
|
2021
Q2 | $467K | Buy |
2,320
+1,347
| +138% | +$282K | 0.05% | 314 |
|
|
2021
Q1 | $209K | Hold |
973
| – | – | 0.02% | 397 |
|
|
2020
Q4 | $229K | Buy |
973
+246
| +34% | +$56.4K | 0.03% | 369 |
|
|
2020
Q3 | $197K | Sell |
727
-173
| -19% | -$47.7K | 0.03% | 378 |
|
|
2020
Q2 | $261K | Sell |
900
-389
| -30% | -$105K | 0.04% | 350 |
|
|
2020
Q1 | $306K | Sell |
1,289
-26
| -2% | -$5.96K | 0.06% | 267 |
|
|
2019
Q4 | $287K | Buy |
1,315
+26
| +2% | +$5.26K | 0.05% | 330 |
|
|
2019
Q3 | $218K | Buy |
1,289
+5
| +0.4% | +$885 | 0.04% | 353 |
|
|
2019
Q2 | $235K | Buy |
+1,284
| New | +$224K | 0.04% | 338 |
|
|
2018
Q2 | – | Sell |
-9
| Closed | -$1K | – | 859 |
|
|
2018
Q1 | $1K | Hold |
9
| – | – | ﹤0.01% | 766 |
|
|
2017
Q4 | $1K | Buy |
+9
| New | +$1.33K | ﹤0.01% | 770 |
|
Other funds holding VRTX
Avior Wealth Management's VRTX Position: Q2 2026 in Review
Avior Wealth Management reduced its Vertex Pharmaceuticals (VRTX) stake by 0.29% in Q2 2026, selling an estimated $3.99K and leaving 3,045 shares worth $1.51M. The position accounts for 0.04% of the portfolio, ranked #290.
Avior Wealth Management first reported a position in VRTX in Q4 2017 and has held it in 31 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Avior Wealth Management held 3,045 shares of Vertex Pharmaceuticals worth $1.51M as of Q2 2026.
- Avior Wealth Management sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
- Vertex Pharmaceuticals made up 0.04% of Avior Wealth Management's portfolio in Q2 2026, its #290 holding.
- Avior Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 31 quarters since.
- 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Avior Wealth Management's 13F filing for Q2 2026, filed 7 Jul 2026.